Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1
DEMAND INFLUENCED BY LOCKDOWN MEASURES
Global in-market sales: CHF 1,005 million, up 0.1% and 49.5% share in the i.v. iron segment of the iron market
4 by value in 2020
5
Net sales of CHF 552.2 million, a decrease of 1.6%, an increase of 3.0% at CER.
Improvements in Q3 in line with the easing of COVID-19 restrictions and better patient access to infusions, followed by a slowdown towards year end as many countries started reintroducing restrictions. Overall utilization of i.v. iron has been highly correlated with intensity of lockdown measures, with recovery to pre-COVID-19 growth levels expected once COVID-19 restrictions are lifted.
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1
cadillacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cadillacnews.com Daily Mail and Mail on Sunday newspapers.
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
<p><span>In February 2021 the trading turnover on the Swiss Stock Exchange reached CHF 110.2 billion, 14.2% less than in the previous month, while the number of transactions decreased by 23.0% to a total of 5,558,306. Since the start of 2021, trading turnover reached CHF 238.6 billion, a decrease of 17.8% compared to the same period in 2020, while the number of trades reached 12,778,315 (-7.4% year-on-year). The SMI® fell by 0.7% and reached 10,522.2 points at the end of February.</span></p>